Therapy
for Treatment-naive Patients
Efficacy
and Impact on Lipids of Reduced Lopinavir/ritonavir Dosing
10/03/06
Lower
Rate of Abacavir Hypersensitivity Reaction among Black Patients 10/03/06
Once-daily
Boosted Fosamprenavir or Atazanavir in Treatment-naive Patients: The ALERT Study
10/03/06
Fixed-dose
Abacavir/3TC Administered Once-daily Compared with Separate Components Twice-daily:
The ALOHA Study 10/03/06
Trizivir
versus Unboosted Atazanavir/AZT/3TC: The ACTION Study 10/03/06
NRTI-sparing
Atazanavir/Efavirenz Regimens Suppress HIV but Raise Lipids 10/03/06
Absence
of Sex Differences in Fosamprenavir Efficacy and Safety
9/29/06
Lower
HAART Adherence Observed Prior to Viral Load "Blips"
9/29/06 When
Does CD4 Cell Count Plateau? Evidence from Patients Treated with Lopinavir/ritonavir
for up to 7 Years
9/29/06 The
KLEAN Study: 48-week Analysis Demonstrates Non-inferiority and Rare Resistance
9/29/06
|
| 